Cindy Tahl's most recent trade in Fate Therapeutics Inc was a trade of 9,037 Common Stock done at an average price of $1.1 . Disclosure was reported to the exchange on Aug. 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | Cindy R. Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 1.06 per share. | 04 Aug 2025 | 9,037 | 397,670 (0%) | 0% | 1.1 | 9,573 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl R. | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl R. | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 70,000 | 406,707 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Cindy Tahl R. | See Remarks | Sale of securities on an exchange or to another person at price $ 1.55 per share. | 10 Jan 2025 | 5,654 | 336,707 (0%) | 0% | 1.6 | 8,764 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 200,000 | 342,361 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 4.37 per share. | 09 Jan 2024 | 10,874 | 142,361 (0%) | 0% | 4.4 | 47,519 | Common Stock |
| Fate Therapeutics Inc | Tahl Cindy | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 2.40 per share. | 09 Nov 2023 | 24,363 | 153,235 (0%) | 0% | 2.4 | 58,471 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 5.24 per share. | 10 Jan 2023 | 11,553 | 177,598 (0%) | 0% | 5.2 | 60,538 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 22.96 per share. | 01 Jun 2022 | 25,000 | 189,151 (0%) | 0% | 23.0 | 574,000 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Jun 2022 | 25,000 | 214,151 (0%) | 0% | 6.6 | 163,750 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2022 | 25,000 | 54,210 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 53,058 | 53,058 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 33,302 | 189,151 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 48.46 per share. | 11 Jan 2022 | 4,883 | 156,385 (0%) | 0% | 48.5 | 236,630 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 49.15 per share. | 11 Jan 2022 | 536 | 155,849 (0%) | 0% | 49.1 | 26,344 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 46.37 per share. | 10 Jan 2022 | 7,095 | 161,911 (0%) | 0% | 46.4 | 328,995 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 47.15 per share. | 10 Jan 2022 | 643 | 161,268 (0%) | 0% | 47.1 | 30,317 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 03 Jan 2022 | 50,000 | 219,006 (0%) | 0% | 6.6 | 327,500 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 50,000 | 66,643 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 59.86 per share. | 03 Jan 2022 | 27,812 | 169,867 (0%) | 0% | 59.9 | 1,664,826 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 58.84 per share. | 03 Jan 2022 | 16,900 | 197,679 (0%) | 0% | 58.8 | 994,396 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 57.76 per share. | 03 Jan 2022 | 4,427 | 214,579 (0%) | 0% | 57.8 | 255,704 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 60.31 per share. | 03 Jan 2022 | 861 | 169,006 (0%) | 0% | 60.3 | 51,927 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 60,958 | 169,006 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Oct 2021 | 50,000 | 158,048 (0%) | 0% | 6.6 | 327,500 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 50,000 | 116,643 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 58.96 per share. | 01 Oct 2021 | 21,844 | 119,892 (0%) | 0% | 59.0 | 1,287,966 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 58.03 per share. | 01 Oct 2021 | 16,312 | 141,736 (0%) | 0% | 58.0 | 946,634 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 59.68 per share. | 01 Oct 2021 | 11,844 | 108,048 (0%) | 0% | 59.7 | 706,862 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 84.56 per share. | 01 Jul 2021 | 50,000 | 108,048 (0%) | 0% | 84.6 | 4,228,000 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 27,685 | 22,315 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.89 per share. | 01 Jul 2021 | 27,685 | 148,199 (0%) | 0% | 4.9 | 135,380 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 15,383 | 166,643 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 01 Jul 2021 | 15,383 | 163,582 (0%) | 0% | 6.6 | 100,759 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 6,932 | 27,628 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.84 per share. | 01 Jul 2021 | 6,932 | 120,514 (0%) | 0% | 4.8 | 33,551 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 5,534 | 0 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.87 per share. | 01 Jul 2021 | 5,534 | 113,582 (0%) | 0% | 7.9 | 43,553 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 94.63 per share. | 01 Jul 2021 | 1,825 | 158,148 (0%) | 0% | 94.6 | 172,694 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 87.90 per share. | 01 Jul 2021 | 1,145 | 162,137 (0%) | 0% | 87.9 | 100,640 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 90.30 per share. | 01 Jul 2021 | 707 | 161,030 (0%) | 0% | 90.3 | 63,843 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 92.26 per share. | 01 Jul 2021 | 432 | 160,373 (0%) | 0% | 92.3 | 39,856 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 93.31 per share. | 01 Jul 2021 | 400 | 159,973 (0%) | 0% | 93.3 | 37,323 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 88.93 per share. | 01 Jul 2021 | 400 | 161,737 (0%) | 0% | 88.9 | 35,573 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 91.07 per share. | 01 Jul 2021 | 225 | 160,805 (0%) | 0% | 91.1 | 20,490 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 86.56 per share. | 01 Jul 2021 | 200 | 163,282 (0%) | 0% | 86.6 | 17,312 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 95.30 per share. | 01 Jul 2021 | 100 | 158,048 (0%) | 0% | 95.3 | 9,530 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 84.83 per share. | 01 Jul 2021 | 100 | 163,482 (0%) | 0% | 84.8 | 8,483 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 01 Apr 2021 | 28,149 | 136,197 (0%) | 0% | 2.9 | 81,632 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 28,149 | 0 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 81.48 per share. | 01 Apr 2021 | 8,220 | 128,828 (0%) | 0% | 81.5 | 669,731 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 86.76 per share. | 01 Apr 2021 | 5,299 | 108,448 (0%) | 0% | 86.8 | 459,733 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 85.98 per share. | 01 Apr 2021 | 4,835 | 113,747 (0%) | 0% | 86.0 | 415,733 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 82.69 per share. | 01 Apr 2021 | 4,556 | 124,272 (0%) | 0% | 82.7 | 376,714 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 83.40 per share. | 01 Apr 2021 | 3,490 | 120,782 (0%) | 0% | 83.4 | 291,080 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 84.48 per share. | 01 Apr 2021 | 2,200 | 118,582 (0%) | 0% | 84.5 | 185,865 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.87 per share. | 01 Apr 2021 | 1,851 | 138,048 (0%) | 0% | 7.9 | 14,567 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 1,851 | 10,458 | - | - | Stock Option Right to Buy | |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 80.49 per share. | 01 Apr 2021 | 1,000 | 137,048 (0%) | 0% | 80.5 | 80,494 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | See Remarks | Sale of securities on an exchange or to another person at price $ 87.45 per share. | 01 Apr 2021 | 400 | 108,048 (0%) | 0% | 87.4 | 34,979 | Common Stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 18,013 | 108,048 (0%) | 0% | 0 | Common stock | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 6,851 | 6,851 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 35,000 | 28,149 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 19 Jan 2021 | 35,000 | 125,035 (0%) | 0% | 2.9 | 101,500 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 114.11 per share. | 19 Jan 2021 | 15,835 | 109,200 (0%) | 0% | 114.1 | 1,806,959 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 115.09 per share. | 19 Jan 2021 | 14,944 | 94,256 (0%) | 0% | 115.1 | 1,719,935 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 115.97 per share. | 19 Jan 2021 | 4,021 | 90,235 (0%) | 0% | 116.0 | 466,333 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 117.06 per share. | 19 Jan 2021 | 200 | 90,035 (0%) | 0% | 117.1 | 23,413 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 117.60 per share. | 08 Jan 2021 | 2,755 | 96,763 (0%) | 0% | 117.6 | 323,985 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 117.15 per share. | 08 Jan 2021 | 2,451 | 94,312 (0%) | 0% | 117.2 | 287,144 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 111.62 per share. | 08 Jan 2021 | 1,332 | 91,957 (0%) | 0% | 111.6 | 148,673 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 110.76 per share. | 08 Jan 2021 | 1,050 | 90,907 (0%) | 0% | 110.8 | 116,296 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 109.65 per share. | 08 Jan 2021 | 872 | 90,035 (0%) | 0% | 109.7 | 95,618 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 115.80 per share. | 08 Jan 2021 | 872 | 93,440 (0%) | 0% | 115.8 | 100,977 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 114.75 per share. | 08 Jan 2021 | 151 | 93,289 (0%) | 0% | 114.8 | 17,328 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 50.41 per share. | 04 Nov 2020 | 51,519 | 99,518 (0%) | 0% | 50.4 | 2,597,140 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 04 Nov 2020 | 51,519 | 151,037 (0%) | 0% | 2.7 | 140,647 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 51,519 | 34,282 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 50.55 per share. | 04 Nov 2020 | 16,682 | 102,118 (0%) | 0% | 50.5 | 843,253 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 10,000 | 63,149 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 04 Nov 2020 | 10,000 | 118,800 (0%) | 0% | 2.9 | 29,000 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 9,282 | 25,000 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 04 Nov 2020 | 9,282 | 108,800 (0%) | 0% | 2.7 | 25,340 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 51.15 per share. | 04 Nov 2020 | 2,600 | 99,518 (0%) | 0% | 51.2 | 132,999 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 16 Oct 2020 | 29,199 | 128,717 (0%) | 0% | 2.7 | 79,713 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 50.25 per share. | 16 Oct 2020 | 29,199 | 99,518 (0%) | 0% | 50.2 | 1,467,212 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 29,199 | 85,801 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 01 Oct 2020 | 35,000 | 134,518 (0%) | 0% | 2.7 | 95,550 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 35,000 | 115,000 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 40.26 per share. | 01 Oct 2020 | 21,757 | 112,761 (0%) | 0% | 40.3 | 875,902 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 41.95 per share. | 01 Oct 2020 | 6,983 | 99,518 (0%) | 0% | 41.9 | 292,929 | Common stock |
| Fate Therapeutics Inc | Cindy Tahl | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 41.09 per share. | 01 Oct 2020 | 6,260 | 106,501 (0%) | 0% | 41.1 | 257,234 | Common stock |